Pasireotide: Deep Dive: How It Works, Who Uses It, and Safety Profile
Medically reviewed by Dr. Sarah Chen, PharmD, BCPS
A deep dive into Pasireotide, a multi-receptor targeted somatostatin analog for Cushing's disease and acromegaly. Learn about its mechanism, uses, and safety.
# Pasireotide: A Deep Dive into How It Works, Who Uses It, and Its Safety Profile
Pasireotide is a next-generation somatostatin analog with a unique receptor binding profile that sets it apart from older drugs in its class. This broader activity makes it a valuable treatment option for Cushing's disease and acromegaly, particularly in patients who have not responded to other therapies. This article provides a deep dive into pasireotide, exploring its mechanism of action, clinical applications, and safety profile.
The Science of Pasireotide: A Multi-Receptor Targeted Approach
Unlike older somatostatin analogs that primarily target the somatostatin receptor 2 (SSTR2), pasireotide has a high affinity for four of the five somatostatin receptor subtypes (SSTR1, 2, 3, and 5). This multi-receptor targeting is particularly important in the treatment of Cushing's disease, as the pituitary tumors that cause this condition often express high levels of SSTR5. By binding to these receptors, pasireotide effectively inhibits the secretion of adrenocorticotropic hormone (ACTH), which in turn reduces the production of cortisol [1]. In acromegaly, its binding to SSTR2 and SSTR5 helps to suppress growth hormone (GH) secretion.
Clinical Applications in Cushing's Disease and Acromegaly
Pasireotide is indicated for the treatment of adult patients with Cushing's disease for whom pituitary surgery is not an option or has not been curative. It is also approved for the treatment of patients with acromegaly who have had an inadequate response to other somatostatin analogs. Clinical trials have shown that pasireotide can significantly reduce cortisol levels in patients with Cushing's disease and GH and IGF-1 levels in patients with acromegaly [2, 3].
Dosing and Administration
Pasireotide is available in two formulations: a subcutaneous injection administered twice daily and a long-acting release (LAR) formulation given as an intramuscular injection once a month. The choice of formulation and dose depends on the indication and the patient's response to treatment [4].
Safety Profile and a Key Side Effect: Hyperglycemia
The safety profile of pasireotide is similar to that of other somatostatin analogs, with common side effects including diarrhea, nausea, and gallstones. However, pasireotide is associated with a higher incidence of hyperglycemia (high blood sugar) than other drugs in its class. This is because its binding to SSTR5 can inhibit insulin secretion. Patients treated with pasireotide require regular monitoring of their blood glucose levels and may need to start or adjust diabetes medications [5].
| Feature | Pasireotide | Octreotide | Lanreotide |
| :--- | :--- | :--- | :--- |
| Mechanism | Multi-receptor Somatostatin Analog | Somatostatin Analog | Somatostatin Analog |
| Indications | Cushing's Disease, Acromegaly | Acromegaly, Carcinoid Tumors | Acromegaly, GEP-NETs |
| SSTR Affinity | SSTR1, 2, 3, 5 | SSTR2 | SSTR2, 5 |
| Hyperglycemia Risk | High | Moderate | Moderate |
Key Takeaways
Pasireotide is a multi-receptor targeted somatostatin analog.
It is used to treat Cushing's disease and acromegaly.
Pasireotide is associated with a higher risk of hyperglycemia than other somatostatin analogs.
Regular blood glucose monitoring is essential for patients treated with pasireotide.
> Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider before starting any peptide therapy or making changes to your health regimen.
References
[1] Pasireotide: Uses, Interactions, Mechanism of Action. https://go.drugbank.com/drugs/DB06663
[2] Clinical use of pasireotide for Cushing's disease in adults - PMC. https://pmc.ncbi.nlm.nih.gov/articles/PMC4370333/
[3] Clinical Review - Pasireotide (Signifor LAR) - NCBI Bookshelf - NIH. https://www.ncbi.nlm.nih.gov/books/NBK619917/
[4] FAQs | SIGNIFOR® LAR (pasireotide). https://signiforlar.com/hcp/cushings-disease/faq/
[5] Pasireotide-induced hyperglycemia in Cushing's disease ... https://pubmed.ncbi.nlm.nih.gov/39735646/
---